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Abstract
Purpose Treatments for breast cancer can lead to chronic musculoskeletal problems. This study aimed to systematically 
review the evidence surrounding the cost-effectiveness of exercise and physiotherapy interventions aimed at reducing the 
risk of physical symptoms and functional limitations due to breast cancer treatment.
Methods A systematic review of the cost-effectiveness of exercise and physiotherapy interventions during and follow-
ing treatment for breast cancer was undertaken according to PRISMA guidelines. Literature searches were carried out in 
Ovid MEDLINE, Ovid Embase, Web of Science, EconLit, CINAHL, PsycINFO, Scopus and the Cochrane Library. Cost-
effectiveness evidence was summarised in a descriptive manner and studies were assessed using quality appraisal tools. The 
review protocol was registered on PROSPERO.
Results A total of 7783 articles were identified and seven were included in the final review. Five studies undertook trial-
based economic evaluations, whereas two studies conducted economic evaluation based on decision models. One study was 
a cost-effectiveness analysis (CEA), three undertook stand-alone cost–utility analyses (CUA) and three studies were com-
bined CEAs and CUAs. Three studies reported favourable cost-effectiveness results for different exercise or physiotherapy 
interventions. In contrast, four studies found that exercise and physiotherapy interventions were not cost-effective on the 
basis of quality-adjusted life year outcomes.
Conclusions The evidence surrounding the cost-effectiveness of exercise and physiotherapy interventions for the treatment 
of breast cancer remains sparse with contrasting conclusions. Future research should particularly aim to broaden the evidence 
base by disentangling the contributing effects of frequency, intensity, time and type of exercise and physiotherapy interven-
tions on cost-effectiveness outcomes.
Keywords Exercise · Rehabilitation · Cost-effectiveness · Systematic review · Economic evaluation
Introduction
Breast cancer is the most common form of cancer amongst 
women in the United Kingdom (UK) with approximately 
50,000 new cases diagnosed each year [1]. Most women 
diagnosed with breast cancer have surgery to the breast 
and axilla, with many also requiring radiotherapy and 
chemotherapy [2, 3]. These treatments can affect the mus-
cles, nerves and lymphatic vessels in the shoulder and upper 
body, resulting in musculoskeletal problems such as limited 
range of motion, weakness, persistent pain, altered sensa-
tions and lymphoedema [4, 5]. Studies suggest that between 
10 and 64% of women have symptoms in their arm or shoul-
der up to 3 years after treatment [6]. These persistent symp-
toms can delay recovery, limit daily activities and impair 
health-related quality of life (HRQoL). It is important that 
the UK National Health Service (NHS) and health systems 
in other countries provide adequate care for women to ensure 
recovery and return to usual activities after cancer treatment.
Exercise interventions may alleviate the side-effects of 
cancer treatment with several systematic reviews of literature 
suggesting they may be clinically effective [7–10]. McNeely 
et al. [8]., for example, reported that exercise improves 
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HRQoL and physical capacity and reduces fatigue in breast 
cancer patients. Furthermore, physical activity can improve 
cardiorespiratory capacity and well-being in cancer patients 
[9].
Although exercise interventions have been shown to be 
clinically effective in several studies, information on their 
cost-effectiveness is sparse. Two systematic reviews, one 
investigating the cost-effectiveness of exercise-based inter-
ventions in the treatment of various chronic diseases [11] 
and the other the cost-effectiveness of cancer rehabilitation 
[10], identified only two economic evaluations of physical 
activity interventions for breast cancer patients [12, 13]. 
The first study reported that a home-based self-managed 
physiotherapy intervention and a supervised group-based 
exercise intervention with psychosocial support were more 
cost-effective than usual care [12]. In contrast, the second 
study concluded that a home-based self-managed exercise 
intervention was not cost-effective compared to an active 
control consisting of flexibility and relaxation activities after 
breast cancer surgery [13].
Given the limited resources in public health systems, 
healthcare interventions should seek to maximise health 
benefits or broader measures of social welfare with the 
resources available. To achieve efficient resource allocation, 
only methods of proven cost-effectiveness should be adopted 
for routine use in the NHS and other publicly funded health 
systems [14–17]. Therefore, the aim of this study was to 
systematically review evidence on the cost-effectiveness of 
exercise and physiotherapy interventions for the treatment of 
breast cancer to inform policy decisions in this clinical area.
Methods
A systematic review of the literature, following Preferred 
Reporting Items for Systematic Review and Meta-Analyses 
(PRISMA) guidelines [18], on the cost-effectiveness of 
exercise and physiotherapy during and following treatment 
for breast cancer was undertaken. Literature searches were 
carried out in Ovid MEDLINE, PubMed, Ovid Embase, 
Web of Science, EconLit, CINAHL, PsycINFO, Scopus 
and The Cochrane Library (including the NHS Economic 
Evaluation Database (NHSEED) electronic databases 
with time horizons covering inception of the databases to 
24 September 2018. Biomedical databases were searched 
using various combinations of keywords and medical subject 
headings (MeSH) based on terms relevant to breast cancer, 
physiotherapy, exercise or physical activity and economic 
evaluation. Further details on the search strategies applied 
to each database are available in the Online Resource 1. 
Searches were not limited by date of publication or lan-
guage. The review protocol was registered on PROSPERO 
(CRD42018108978).
Selection criteria
Economic evaluations of exercise and physiotherapy inter-
ventions for breast cancer patients were considered. Eligi-
ble types of economic evaluations included cost-effective-
ness analyses, cost–benefit analyses, cost–utility analyses, 
cost consequences analyses and cost-minimisation analy-
ses. Each study was required to have reported both costs 
and consequences and compared an experimental interven-
tion to at least one other intervention or control. Partici-
pants included in the selected studies were adults with a 
confirmed breast cancer diagnosis who were undergoing 
or had received treatment, including any surgical removal 
of breast tumour, e.g. mastectomy (simple, modified or 
radical), local wide excision or lumpectomy and/or axil-
lary surgery (lymph node dissection/clearance or sentinel 
lymph node biopsy (SNB/SNLB) or dissection. An exer-
cise or physiotherapy intervention was defined as one that 
included an exercise intervention delivered and supported 
or unsupported by a physiotherapist or other health profes-
sional. Comparators included usual care/control, different 
types of exercises or no exercise. Descriptions of usual 
care/control were extracted from primary reports. Out-
come measures included measures of cost-effectiveness, 
e.g. an incremental cost-effectiveness ratio (ICER) or a 
measure of net monetary benefit (NMB). All identified 
titles and abstracts were screened independently by two 
authors (KK and BM) and, where relevant, full-text arti-
cles were obtained and assessed against the study inclusion 
criteria. Disagreements at each stage (title and abstract 
stage, full report stage) were resolved by discussion or 
referred to a third author (SP) for final assessment.
Data extraction
Data extraction was carried out by one reviewer (KK) 
and checked by a second reviewer (BM). Any disagree-
ments were resolved through discussion or through 
a final assessment by a third reviewer (SP). Data were 
extracted using a standardised form. Extracted data items 
included author(s), year of publication, country and set-
ting, patient characteristics, intervention and compara-
tor details, main analytical approaches (e.g. patient-level 
analysis or decision-analytic modelling) and the primary 
outcome(s) specified for the economic analysis. In addi-
tion, details of estimation and adjustment for HRQoL, key 
assumptions made in the base case or tested in sensitivity 
analyses, direct costs (medical and non-medical) and pro-
ductivity costs estimated, estimates of cost-effectiveness 
and approaches to quantifying uncertainty (e.g. decision 
uncertainty to address uncertainty around the value of 
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the cost-effectiveness threshold, probabilistic sensitivity 
analysis to address uncertainty surrounding the value of 
parameter inputs) were extracted.
Quality assessment
The quality of reporting by the economic evaluations was 
assessed using the Consolidated Health Economic Evalu-
ation Reporting Standards (CHEERS) checklist [19]. The 
quality of each economic evaluation was scored using 
CHEERS criteria, which allows overall scores from 0 to 24 
(24 representing the best score possible). In addition, the 
methodological quality of any randomised controlled trial 
underpinning an economic evaluation was assessed using 
the Cochrane Collaboration’s risk of bias tool [20]. The 
risk of bias domains included random sequence generation, 
allocation concealment, blinding of participants, blinding 
of personnel, blinding of outcome assessment, incomplete 
outcome data and selective outcome reporting. Each domain 
was classified as of low, high or unclear risk [20]. Where 
studies failed to report an item, it was classified as unclear.
Analysis
Cost data extracted from studies were inflated, where neces-
sary, to 2016 prices using the relevant country-specific Gross 
Domestic Product (GDP) deflator index, and subsequently 
converted, where necessary, from their respective currencies 
into US dollars using purchasing power parities supplied by 
the Organisation for Economic Co-operation and Develop-
ment (OECD) [21]. For studies that failed to report their 
currency price dates, it was assumed that the costs used in 
the valuation process applied to the financial year prior to 
the publication of the study.
Methodological variations between studies, including 
variations in underpinning health care practices across juris-
dictions and variations in the relative prices of labour and 
capital inputs across jurisdictions, prevented a pooling of 
economic data akin to meta-analyses performed on clinical 
effectiveness estimates. Rather, cost-effectiveness estimates 
and broader economic outcomes are presented in a descrip-
tive manner according to broad economic design.
Results
Search results
In total, 14,636 records were identified from the biblio-
graphic searches. After removing 6853 duplicates, 7783 
titles and abstracts were reviewed and 7773 articles were 
subsequently excluded at the title and abstract screening 
stage (Fig. 1). Common reasons for exclusion were that the 
studies were not economic evaluations, the population did 
not include breast cancer patients or the intervention was 
not exercise or physiotherapy based. Ten articles fulfilled 
screening criteria and were retrieved for full-text analysis; of 
these, seven fulfilled the study inclusion criteria. Two stud-
ies were excluded at the full report stage because they were 
not economic evaluations [22, 23], whilst a third study by 
Kampschoff and colleagues [24] presented only aggregated 
results across breast and colon cancer patients and it was not 
possible to obtain data only for breast cancer (Fig. 1). Of the 
seven included studies, one study by Perrier and colleagues 
[25] was reported as a conference poster and further details 
were obtained directly from the authors.
Study characteristics
Descriptive information (study design, patient characteris-
tics, interventions, outcomes) pertaining to each included 
study is presented in Table 1. Classified by country of origin, 
three studies were conducted in the Netherlands, three con-
ducted in Australia and one in France. Five studies carried 
out trial-based economic evaluations [13, 25–28], whereas 
two studies conducted economic evaluation based on deci-
sion models [12, 29]. A decision model theoretically allows 
for the extrapolation of costs and effects beyond the time 
horizon of trial data, can reflect all appropriate evidence, 
can compare all relevant options and can make head-to-head 
comparisons of alternative competing interventions when 
relevant trials do not exist [30, 31]. The study by Gordon 
et al. [12] made head-to-head comparisons of alternative 
competing interventions without trial-based data, whereas 
Mewes et al. [29] used decision modelling to extrapolate 
costs and effects beyond the time horizon of the trial data 
used [32].
Interventions and outcomes
The type of physiotherapy and exercise interventions evalu-
ated by the studies included home-based self-managed 
exercises [13, 28, 29], home-based self-managed and super-
vised physiotherapy [12], home-based supervised exercises 
with different delivery methods (face-to-face or over-the-
telephone) [26] and group-based supervised exercise pro-
grammes [12, 25, 27, 28]. The physiotherapy and exercise 
interventions targeted a range of health and fitness goals 
including strength and flexibility, balance, endurance and 
overall fitness (Table 1). The range of control interventions 
included usual care [12, 26, 27, 29], a sham intervention 
(active control of flexibility and relaxation activities) [13], 
dietary advice [25] and usual care with no routine exer-
cise [28]. For the five studies using trial data, the primary 
outcome measures included the self-report Functional 
Assessment of Cancer Therapy—Breast Cancer version 4 
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(FACT-B + 4) [26], EuroQol 5-dimension questionnaire 3 
level (EQ-5D-3L) [13], European Organisation for Research 
and Treatment of Cancer core quality of life questionnaire 
(EORTC QLC-C30) [13], cardiorespiratory fitness [28] and 
the multidimensional fatigue inventory (MFI) and fatigue 
quality list (FQI) [27].
Economic evaluations
Information relating to the characteristics and economic out-
comes of the economic evaluations is presented in Table 2. 
All economic evaluations were published between 2005 
and 2018. One study was cost-effectiveness analysis (CEA) 
[25], three were stand-alone cost–utility analyses (CUAs) 
[13, 27, 29] and three were combined CEAs and CUAs [12, 
26, 28]. Four studies adopted a societal perspective [12, 13, 
27, 28], whilst one adopted a health care system perspective 
[29], one a private and service provider perspective [26] 
and one a national insurance perspective [25]. The mean 
total costs per patient for delivering group exercise inter-
ventions ranged from AUS$342 (US$327, 2016 prices) for 
a home-based physiotherapy intervention [12] to €31,133 
(US$38,819, 2016 prices) for a home-based, low-intensity, 
individualised, self-managed physical activity programme 
with the addition of behavioural reinforcement [28]. The 
primary measure(s) of health consequence included in the 
seven economic evaluations fell into the following catego-
ries: number of rehabilitated cases and quality-adjusted life-
years (QALYs) [12, 26]; change in body mass index (BMI) 
and cardiorespiratory fitness [25]; fatigue and QALYs [28] 
and QALYs alone [13, 27, 29]. QALYs were derived from 
the EQ-5D-3L measure in four studies [13, 26–28], whilst 
in one study [12], QALYs were generated by multiplying 
period of life by utility scores obtained using a single-item 
linear analogue scale entitled the Subjective Health Estima-
tion (SHE) scale which had been developed and validated by 
the International Breast Cancer Study Group [33]. A further 
study used a mapping algorithm to estimate EQ-5D utility 
scores from the short-form six dimension health index (SF-
6D) and then used those values to calculate QALYs [29].
Quality of studies
The methodological quality assessment of the economic 
evaluations as judged by the CHEERS checklist produced 
scores ranging from 19 to 22 (Online Resource 2). For risk 
Articles identified through 
database searching          
(n = 14,636)
Articles excluded based     
on title and abstract            
(n=7,773)
Reasons for exclusion:
Not an economic evaluation 
(n=7,730)
Not breast cancer patients (n=25)
Non exercise or rehabilitation 
intervention (n=18)





Articles excluded based        
on full-text article            
(n=3)
Not an economic evaluation 
(n=2)
Aggregated data for combined 
colon and breast cancer patients 
only (n=1)
Articles after              
duplicates removed         
(n = 7,783)
Fig. 1  PRISMA flow diagram
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of bias, although there were five studies that carried out trial-
based economic evaluations [13, 25–28], Mewes et al. [29] 
used a decision model that drew upon data from a trial [32]; 
therefore, risk of bias results are presented for six studies. 
The methodological assessment of risk of bias was con-
sistent across studies (Fig. 2, Online Resource 3) with the 
majority of studies considered at low of risk of bias for the 
majority of domains. However, all studies were considered 
at high risk of bias for the domain “blinding of participants 
and personnel” due to the unconcealed nature of the exercise 
and physiotherapy interventions.
Summary of results of economic evaluations
The results pertaining to the cost-effectiveness of the exer-
cise and physiotherapy interventions for breast cancer 
patients evaluated are summarised in Table 2.
Cost‑effectiveness studies
Only one economic evaluation, a study conducted in France, 
reported non-QALY based results alone and found that a 
supervised group-based intervention dominated usual care 
(i.e. generated improved health outcomes and lower overall 
costs, on average) with a negative ICER of €-11,159 per 
decline in BMI unit [25]. The results for cardiorespiratory 
fitness also showed that the intervention dominated usual 
care with a negative ICER of €-6030 per estimated aerobic 
capacity unit gained for  VO2max [25]. Probabilistic sensitiv-
ity analyses conducted by the authors showed that the prob-
ability that the intervention is cost-effective reached 56% 
based on the BMI outcome and 69% based on the VO2max 
outcome [25].
Cost–utility studies
Three economic evaluations estimated cost-effectiveness 
results using the QALY framework alone [13, 27, 29]. 
One Australian study reported that a home-based self-
managed exercise intervention was not cost-effective, 
with only a 5% probability that it was both less costly 
and more effective than the control [13]. The second 
study, from the Netherlands, found that a supervised 
group-based exercise intervention was not cost-effective 
compared with usual care with an ICER of €291,200 per 
QALY gained (US$375,572, 2016 prices) [27]. Scenario 
analysis, where the cost-effectiveness was considered 
from a healthcare perspective, provided similar to results 
of the baseline analysis [27]. The third study, also from 
the Netherlands, found that a home-based self-managed 
exercise intervention generated an ICER of €28,078 
(US$35,707, 2016 prices) per QALY gained and the 
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because the ICER of €28,078 fell below recommended 
cost-effectiveness thresholds [29]. Sensitivity analyses 
found that the outcomes were influenced by, first, util-
ity values for the “menopausal symptoms” and “reduc-
tion in menopausal symptoms” health states and, second, 
the duration of the treatment effect, with shorter effect 
duration resulting in lower cost-effectiveness. The out-
comes of this study were most sensitive to a reduction 
of the duration of the treatment effect from 5 to 3 and 
1.5 years [29].
Fig. 2  Risk of bias assessment
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Combined cost‑effectiveness and cost–utility 
studies
Three studies estimated cost-effectiveness results using both 
QALY and non-QALY frameworks. An Australian study 
showed that a home-based self-managed and supervised 
physiotherapy intervention (ICER: AUS$ 1344 (US$1284) 
per QALY, 2016 prices) and a supervised group-based exer-
cise and psychosocial intervention (ICER: AUS$ 14,478 
(US$13,831) per QALY, 2016 prices) were both more effec-
tive than usual care, with the home-based intervention being 
the more cost-effective of the two experimental interventions 
[12]. In contrast, the results based on rehabilitated cases 
showed that usual care was less costly and more effective 
than both the home-based physiotherapy and group-based 
exercise and psychosocial interventions [12]. The ICERs for 
the two experimental interventions remained robust to sev-
eral sensitivity analyses, with the exception of variations in 
utility scores to the lower limits of confidence intervals when 
QALYs were the outcome used. The authors conducted post 
hoc analyses to check whether self-reported function (FACT-
B + 4) (used to estimate rehabilitated cases) and health util-
ity scores (derived from Subjective Health Estimation scale) 
measured different concepts; they found that the measures 
were only modestly correlated (coefficient = 0.54, p < 0.001), 
which signified that the two outcome measures were suf-
ficiently different and therefore different cost-effectiveness 
conclusions were possible given the study design [12].
Another Australian study reported that a home-based 
supervised exercise intervention was not cost-effective 
from either a health service provider (ICER: AUS$ 105,231 
(US$73,786) per QALY, 2016 prices) or a private payer per-
spective (ICER: AUS$ 90,842 (US$63,697) per QALY, 2016 
prices) [26]. In contrast, the authors reported that results 
based on rehabilitated cases showed that the home-based 
supervised exercise intervention was cost-effective, with an 
ICER of approximately AUS$2400 (US$1677, 2016 prices) 
per improver [26]. Sensitivity analyses indicated that the 
incremental cost-effectiveness ratios using QALYs gained 
were most sensitive to variations in EQ-5D-3L utility values 
within 95% confidence limits. Other variations in variables 
tested produced negligible changes to the incremental cost-
effectiveness ratios. The likelihood of the service provider 
model being cost-effective was 44.4%, and 46.3% for the pri-
vate model, at a cost-effectiveness threshold of AUS$50,000 
per QALY gain. The authors concluded that whilst QALYs 
are the preferred measure of health consequence in health 
economic evaluations, there are a couple of reasons why 
they may not have been appropriate for this clinical context. 
Firstly, the intervention duration was not expected to extend 
participant survival during the trial period. Secondly, the 
mean health utility weight for the study participants (0.84) 
was similar to that reported for the Australian general 
population. Therefore, detecting differences in QALYs was 
deemed unrealistic in their sample [26].
A third study, conducted in the Netherlands, reported 
that a supervised exercise intervention was borderline cost-
effective compared to usual care with an ICER of €26,916 
(US$33,561, 2016 prices) per QALY gained [28]. The 
authors report that the non-QALY based results for this 
intervention suggest that it is cost-effective in terms of cost 
per unit change in general fatigue (ICER of €788), and cost 
per unit change in physical fatigue (ICER of €1402) [28]. 
The same study showed that a home-based self-managed 
exercise with the addition of behavioural reinforcement was 
not cost-effective compared with usual care with an ICER 
of €70,052 (US$87,347, 2016 prices) per QALY gained 
[28]. In contrast, the authors reported that home-based self-
managed exercise with the addition of behavioural reinforce-
ment is cost-effective in terms of cost per unit change in 
general fatigue (ICER of €4711), and cost per unit change 
in physical fatigue (ICER of €10,384) [28]. Scenario analy-
ses conducted by the authors found that the probability of 
cost-effectiveness for both comparators was greater amongst 
compliant participants [28].
Discussion
Evidence on the cost-effectiveness of exercise and physi-
otherapy interventions for the treatment of breast cancer was 
systematically assessed in this review. We identified only 
seven studies reporting on the cost-effectiveness of exercise 
and physiotherapy interventions for breast cancer patients 
[12, 13, 25–29], which between them evaluated nine differ-
ent exercise-based interventions. These studies were gen-
erally of high quality and at low risk of bias. There have 
been two previous reviews that have reported evidence on 
the cost-effectiveness of exercise-based interventions in 
the treatment of breast cancer. The first review by Roine 
et al. [11] identified a single study, which reported that a 
home-based self-managed physiotherapy intervention and a 
supervised group-based exercise intervention with psycho-
social support were more cost-effective than usual care [12]; 
this study is included in our review. The second review by 
Mewes et al. [10] also only identified a single study, which 
concluded that a home-based self-managed exercise inter-
vention was not cost-effective compared to an active control 
consisting of flexibility and relaxation activities after breast 
cancer surgery [13]; this study is also included in our review.
Using QALYs as the primary measure of health conse-
quence, the evidence surrounding the cost-effectiveness of 
exercise and physiotherapy interventions for breast can-
cer rehabilitation following surgery was equivocal. Three 
studies reported favourable cost-effectiveness results for 
different exercise or physiotherapy interventions [12, 28, 
50 Breast Cancer Research and Treatment (2019) 176:37–52
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29]. In contrast, four studies conducted in different patient 
populations and healthcare settings found that exercise or 
physiotherapy interventions were not cost-effective using 
the QALY framework and on the basis of recommended 
country-specific cost-effectiveness thresholds for the 
QALY metric [13, 26–28].
Cost-effectiveness evidence was only reported within 
three countries, each with different healthcare systems 
(Australia, The Netherlands and France). This cost-effec-
tiveness evidence was largely based on small studies with 
sample sizes ranging from 60 to 244 women. Methodologi-
cal variations in recommended approaches across jurisdic-
tions to the conduct of health economic evaluations may 
partly explain variations in cost-effectiveness results. For 
example, not all studies using the QALY framework for the 
analyses estimated QALYs using the same multi-attribute 
utility measure. The EQ-5D-3L was used in four studies 
[13, 26–28], whilst one study used utilities derived from 
the SHE [12] and a further study relied upon an exter-
nal mapping algorithm [29]. Furthermore, variations in 
the content and delivery of exercise and physiotherapy 
interventions and the relative prices of the resource com-
ponents of those interventions and their resource conse-
quences are also likely to be factors driving the lack of 
consistency in findings. Consequently, any variation in 
cost-effectiveness estimates is likely to be driven, at least 
in part, by variations in methodological factors, as well 
as variations in the essential features of the interventions 
evaluated.
The comparators considered by the studies included in 
this systematic review can broadly be categorised as post-
operative exercise versus control [12, 26], exercise versus 
control during adjuvant breast cancer treatment [13, 25, 
27, 28] and exercise versus control following breast cancer 
treatment [29]. We found no economic evaluations compar-
ing post-operative early versus delayed exercise interven-
tions despite evidence for their clinical effectiveness [8]. 
Clearly, there is a need for further research that assesses the 
cost-effectiveness of the broad range of exercise and physi-
otherapy interventions that have been developed, many of 
which are used in routine clinical practice. A particular focus 
of future research should be to disentangle the contributing 
effects of frequency, intensity, time and type of exercise and 
physiotherapy interventions on cost-effectiveness outcomes 
with the view to specifying the relationship between fea-
tures of those interventions and cost-effectiveness outcomes. 
Furthermore, although all but one study included in this 
systematic review measured health consequences in terms 
of QALYs, which are widely recommended for cost-effec-
tiveness-based decision-making, there is a need for assess-
ments of the sensitivity of widely used multi-attribute utility 
measures such as the EQ-5D-3L to changes in outcomes of 
interest, such as symptoms of fatigue [8].
The key strength of this study is the robust methodology 
adopted, which included following recommended guide-
lines for the conduct of systematic reviews of economic 
evaluations [18], and a transparent approach to study 
identification, assessment, data extraction and critical 
appraisal. Variations in methodological approaches and 
factors precluded the use of meta-analysis for combining 
cost-effectiveness evidence across studies, in line with 
other systematic reviews of economic evaluations [35, 
36]. The study does have limitations, which should be 
borne in mind by readers. First, we did not search grey lit-
erature databases, including TRIP and Open Grey, within 
our search strategies. We worked closely with an infor-
mation specialist to develop, test and refine our search 
strategies, but cannot preclude the possibility of exclusion 
of potentially relevant studies. Second, interpretation of 
the cost-effectiveness assessments that measured health 
consequences in terms of natural or biomedical units of 
outcomes, such as changes in BMI or cardiorespiratory 
fitness [25], is constrained by the absence of external cost-
effectiveness thresholds for these health consequences. 
External evidence from stated or revealed preference stud-
ies on the value that should be placed on these effects will 
be required for the purposes of cost-effectiveness-based 
decision-making.
Conclusion
This review has highlighted that the evidence base sur-
rounding the cost-effectiveness of exercise and physi-
otherapy interventions for the treatment of breast can-
cer remains sparse with contrasting conclusions. Future 
research should particularly aim to broaden the evidence 
base by disentangling the contributing effects of fre-
quency, intensity, time and type of exercise and physi-
otherapy interventions on cost-effectiveness outcomes.
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